ArticleAlzheimer's research & therapy2013
Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease.
Article in Alzheimer's research & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- Culture Dimensionality Regulates Protein Expression and Bioactivity in THP-1-Derived Macrophages.Biomedicines · 2026Article
- Identification of Immune-Related Biomarkers of Schizophrenia in the Central Nervous System Using Bioinformatic Methods and Machine Learning Algorithms.Molecular neurobiology · 2025Article
- Transmembrane and coiled-coil 2 associates with Alzheimer's disease pathology in the human brain.Brain pathology (Zurich, Switzerland) · 2025Article
- Platelet Dynamics in Neurodegenerative Disorders: Investigating the Role of Platelets in Neurological Pathology.Journal of clinical medicine · 2024Review
- The platelet transcriptome and proteome in Alzheimer's disease and aging: an exploratory cross-sectional study.Frontiers in molecular biosciences · 2023Article
- Platelet-promoting drug delivery efficiency for inhibition of tumor growth, metastasis, and recurrence.Frontiers in oncology · 2022Review
- Correction to: Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease.Alzheimer's research & therapy · 2021Article
- Article
- Integrin αIIbβ3 outside-in signaling activates human platelets through serine 24 phosphorylation of Disabled-2.Cell & bioscience · 2021Article
- The canine activated platelet secretome (CAPS): A translational model of thrombin-evoked platelet activation response.Research and practice in thrombosis and haemostasis · 2021Article
- Recent Evidence in Epigenomics and Proteomics Biomarkers for Early and Minimally Invasive Diagnosis of Alzheimer's and Parkinson's Diseases.Current neuropharmacology · 2021Review
- Platelets in Healthy and Disease States: From Biomarkers Discovery to Drug Targets Identification by Proteomics.International journal of molecular sciences · 2020Review
- Network Analysis of a Membrane-Enriched Brain Proteome across Stages of Alzheimer's Disease.Proteomes · 2019Article
- The Delivery Strategy of Paclitaxel Nanostructured Lipid Carrier Coated with Platelet Membrane.Cancers · 2019Article
- Proteomic analysis reveals that wildtype and alanine-expanded nuclear poly(A)-binding protein exhibit differential interactions in skeletal muscle.The Journal of biological chemistry · 2019Article
- Plasma Gelsolin: Indicator of Inflammation and Its Potential as a Diagnostic Tool and Therapeutic Target.International journal of molecular sciences · 2018Review
- The polyadenosine RNA-binding protein ZC3H14 interacts with the THO complex and coordinately regulates the processing of neuronal transcripts.Nucleic acids research · 2018Article
- MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer's disease.Human molecular genetics · 2017Article
- Changes in the detergent-insoluble brain proteome linked to amyloid and tau in Alzheimer's Disease progression.Proteomics · 2016Article
- Anticancer Platelet-Mimicking Nanovehicles.Advanced materials (Deerfield Beach, Fla.) · 2015Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
introductionPeripheral biomarkers to diagnose Alzheimer's disease (AD) have not been established. Given parallels between neuron and platelet biology, we hypothesized platelet membrane-associated protein changes may differentiate patients clinically defined with probable AD from noncognitive impaired controls.
methodsPurified platelets, confirmed by flow cytometry were obtained from individuals before fractionation by ultracentrifugation. Following a comparison of individual membrane fractions by SDS-PAGE for general proteome uniformity, equal protein weight from the membrane fractions for five representative samples from AD and five samples from controls were pooled. AD and control protein pools were further divided into molecular weight regions by one-dimensional SDS-PAGE, prior to digestion in gel. Tryptic peptides were analyzed by reverse-phase liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). Ionized peptide intensities were averaged for each identified protein in the two pools, thereby measuring relative protein abundance between the two membrane protein pools. Log2-transformed ratio (AD/control) of protein abundances fit a normal distribution, thereby permitting determination of significantly changed protein abundances in the AD pool.
resultsWe report a comparative analysis of the membrane-enriched platelet proteome between patients with mild to moderate AD and cognitively normal, healthy subjects. A total of 144 proteins were determined significantly altered in the platelet membrane proteome from patients with probable AD. In particular, secretory (alpha) granule proteins were dramatically reduced in AD. Of these, we confirmed significant reduction of thrombospondin-1 (THBS1) in the AD platelet membrane proteome by immunoblotting. There was a high protein-protein connectivity of proteins in other pathways implicated by proteomic changes to the proteins that define secretory granules.
conclusionsDepletion of secretory granule proteins is consistent with a preponderance of post-activated platelets in circulation in AD. Significantly changed pathways implicate additional AD-related defects in platelet glycoprotein synthesis, lipid homeostasis, amyloidogenic proteins, and regulators of protease activity, many of which may be useful plasma membrane-expressed markers for AD. This study highlights the utility of LC-MS/MS to quantify human platelet membrane proteins and suggests that platelets may serve as a source of blood-based biomarkers in neurodegenerative disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.